Anticancer Innovative Therapy Congress : highlights from the 10th anniversary edition

De Santis, F ORCID: https://orcid.org/0000-0001-5877-0639, Fucà, G, Schadendorf, D, Mantovani, A ORCID: https://orcid.org/0000-0001-5578-236X, Magnani, L, Lisanti, MP ORCID: https://orcid.org/0000-0003-2034-1382, Pettitt, S, Bellone, M, Del Sal, G, Minucci, S, Eggermont, A, Bruzzi, P, Bicciato, S ORCID: https://orcid.org/0000-0002-1944-7078, Conte, P, Noberini, R ORCID: https://orcid.org/0000-0002-7267-1079, Hiscott, J, De Braud, F, Del Vecchio, M and Di Nicola, M 2021, 'Anticancer Innovative Therapy Congress : highlights from the 10th anniversary edition' , Cytokine & Growth Factor Reviews, 59 , pp. 1-8.

Preview

PDF - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (2MB) | Preview

Abstract

During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell–based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.

Item Type:	Article
Additional Information:	** Article version: AM ** Embargo end date: 31-12-9999 ** From Elsevier via Jisc Publications Router ** Licence for AM version of this article: This article is under embargo with an end date yet to be finalised. **Journal IDs: issn 13596101 **History: issue date 14-02-2021; accepted 09-02-2021
Schools:	Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title:	Cytokine & Growth Factor Reviews
Publisher:	Elsevier
ISSN:	1359-6101
Related URLs:	Publication
SWORD Depositor:	Publications Router
Depositing User:	Publications Router
Date Deposited:	17 Feb 2021 09:39
Last Modified:	15 Feb 2022 16:30
URI:	https://usir.salford.ac.uk/id/eprint/59600

Actions (login required)

Edit record (repository staff only)